Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Glucagon And Epinephrine Continue To Drive Growth At Amphastar
Amphastar has delivered another successful quarter, bolstered by sales of glucagon and epinephrine, as it prepares to roll out a number of commercially attractive products and complete a significant branded product acquisition.
Lilly Offloads Baqsimi To Amphastar While Investing In Mounjaro Head-To-Head Trial
Although Lilly said the glucagon spray’s relatively low sales were not a factor, the pharma may be prioritizing investment on its newer diabetes and weight-loss drug Mounjaro.
Troriluzole Fails First Phase III Test As Biohaven Looks Beyond Migraine
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.